Pear Therapeutics Announces Publication Showing Cost Savings and Decreased Hospital Encounters for Opioid Use Disorder Patients Treated with reSET-O® Compared to Control Patients During Nine-Month Period Following Prescription
reSET-O® is the first and only FDA-authorized prescription digital therapeutic (PDT) for patients with